Press release
May 12, 2026
SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights
SAB Biotherapeutics, Inc. (SABS)
Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027 Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in